The FDA has approved GSK’s Hibsago for adults with chronic hepatitis B virus infection who meet specific virological criteria ...

Microbiotica has presented new phase 1b clinical data for MB097, its oral precision microbiome therapeutic for advanced melanoma, at the ESMO Congress 2026 in Madrid. The MELODY1 ...

Johnson & Johnson has secured European Commission approval for an indication extension of teclistamab monotherapy for adults ...

The FDA has approved Genentech’s Enspryng for adults with thyroid eye disease, making it the first at‑home subcutaneous ...

Sitryx Therapeutics has announced positive topline phase 1b results for SYX-5219, a first-in-class oral PKM2 modulator being ...

ViiV Healthcare has signed an agreement appointing Axmed as a non-exclusive distributor to support procurement and supply of ...

Galderma has announced new NEMLUVIO data to be presented at Fall Clinical 2026, including a post‑hoc analysis from the ...

Lundbeck has reported results from an open‑label phase 1b trial evaluating Lu AF28996, an investigational oral prodrug of a ...

Bespak has signed an MOU with SNBL to provide immediate and exclusive global access to SNBL’s proprietary nasal dry powder ...

Merz Therapeutics has completed patient recruitment in two global phase 3 trials evaluating XEOMIN (incobotulinumtoxinA) for ...

Johnson & Johnson has announced that the CHMP recommends approval of an indication extension for TALVEY (talquetamab) plus ...

Osivax has reported phase 2b results for OVX836 and outlined the next stage of development for its next-generation seasonal ...